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Questioning flecainide’s
mechanism of action in the
treatment of catecholaminergic
polymorphic ventricular
tachycardia
Flecainide attenuates cardiac Ca2+ cycling
abnormalities in malignant catecholamine-
triggered arrhythmias but its mechanism of
action remains highly contentious. We read
with interest the study of Yang et al. (2016)
that used in silico predictions in an attempt
to determine the relative contribution of
block by flecainide of ryanodine receptor
2 (RyR2) and the Na+ channel to the
overall therapeutic effect of this drug in
catecholaminergic polymorphic ventricular
tachycardia (CPVT). Flecainide’s actions
were modelled by considering its inhibition
of the Na+ current (INa) and RyR2 in
combination and individually. The authors
conclude that the effects of the drug on
Na+ channels are insufficient to explain its
efficacy in CPVT, while its block of RyR2
alone was as effective as the combined block
of INa and RyR2.
Our concerns about the usefulness of this
approach are twofold:
(1) Purported block of RyR2 by flecainide
The blocking parameters used in Yang
et al. (2016) are based on values reported
in Hilliard et al. (2010) and subsequent
publications from the same group. The
major problem with the use of these
parameters to model open channel block
by flecainide of RyR2-mediatedCa2+ release
from the sarcoplasmic reticulum (SR)
is that Hilliard et al. (2010) did not
demonstrate block of this current, rather
they reported partial block of K+ movement
in the opposite (cytosol to luminal)
direction.
To fully understand the problem it is
necessary to outline some basic features of
RyR2 channel structure and function.
RyR2 provides a ligand-regulated pathway
for the release of Ca2+ from the cardiac
SR to initiate myocyte contraction. In its
open conformation Ca2+ flows through the
pore-forming region (PFR) of RyR2, down
its concentration gradient, from the SR
lumen to the cytosol. The key structural
features of the RyR2 PFR, based on recent
high-resolution cryo-electron microscopy
investigations (Yan et al. 2014), are shown
schematically in Fig. 1. Ca2+ leaving the SR
enters the luminal mouth of the open PFR
before passing through a region equivalent
to the selectivity filter of the more discri-
minating monovalent-selective channels
and eventually into a large, water-filled,
lumen lumen
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Figure 1. Ionic fluxes and interaction of flecainide in RyR2
A, schematic representation of the location and orientation of RyR2 in the cardiac myocyte SR
membrane system. The trans-membrane domain contains the pore-forming region (PFR) and the
large cytosolic domain abuts transverse tubule invaginations of the sarcolemma. B–G, schematic
diagrams depicting the open RyR2 PFR (B, indicated by circle) together with relevant cation fluxes
and interactions of flecainide (green octagon). Only two of the four PFR monomers are shown
for clarity. C, to initiate contraction Ca2+ is released from the SR, flowing down its concentration
gradient through the open RyR2 PFR. D, to dissipate the diffusion potential generated by Ca2+
release, a counter current of K+ flows from the cytosol to the SR lumen, at least in part through
RyR2. E, the RyR2 blocking parameters used in Yang et al. (2016) are based on data reported in
Hilliard et al. (2010) that describe the effects of flecainide on the cytosolic to luminal flux of K+.
F, under these conditions flecainide enters the cytosolic cavity of RyR2 and partially occludes
the pore. G, the physiologically relevant flux of Ca2+ from the lumen to the cytosol displaces
flecainide (Bannister et al. 2015). As a consequence open channel block of RyR2 by flecainide
can play no part in the effectiveness of this drug in the treatment of CPVT.
cytosolic cavity contiguous with the bulk
cytosol, lined with trans-membrane helices
(Fig. 1C). RyR2-mediated Ca2+ release is
an electrogenic process during which a
charge-compensating K+ counter current
flows from the cytosol into the SR, at least
in part, through RyR2 (Fig. 1D).
C© 2016 The Authors The Journal of Physiology published by John Wiley & Sons Ltd on behalf of The Physiological Society DOI: 10.1113/JP272497
This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution
and reproduction in any medium, provided the original work is properly cited.
6432 Letter J Physiol 594.21
To monitor flecainide’s actions on RyR2
Hilliard et al. (2010) incorporated channels
into phospholipid bilayers and measured
K+ flux under voltage clamp conditions.
RyR2 incorporates into the bilayer in a
fixed orientation so that its configuration
is defined. In these investigations, the net
direction of K+ flux through RyR2was from
the cytosolic to luminal side of the channel,
driven by a trans-membrane potential with
the solution at the cytosolic side held at
+40 mV relative to that at the luminal
side of the channel (Fig. 1E). Flecainide
was added to the cytosolic solution and,
from here, interacts with RyR2 (Fig. 1F).
When bound, flecainide partially occludes
the RyR2 PFR and individual blocking
events are resolved with dwell-times in the
millisecond range. A residual current of
20% of the full open current continues
to flow with flecainide bound. The key
point of our comment on the work of
Yang et al. (2016) is that the experiments
of Hilliard et al.(2010) merely demonstrate
block of cytosolic to luminal flux of K+
through RyR2; they provide no information
on the ability of flecainide to block the
flux of cations, and in particular Ca2+,
in the physiologically relevant direction
through RyR2, that is, from the SR lumen
to the cytosol. For this reason the use of
parameters of block determined by Hilliard
et al. (2010) in the models described in
Yang et al. (2016) is inappropriate and
irrelevant and their conclusion that the
action of flecainide on RyR2 is sufficient
to explain flecainide efficacy in CPVT, is
unsound.
The possibility that block by flecainide
could influence RyR2-mediated Ca2+
release was examined in Bannister et al.
(2015) using individual recombinant
human RyR2 channels in planar bilayers. In
these investigations we demonstrated that
flecainide limits cytosolic to luminal K+ flux
through RyR2 by interacting at a site within
the cytosolic cavity of the PFR. Flecainide
only has access to this site from the cyto-
sol and, crucially, the affinity with which
flecainide is bound is insufficient to pre-
vent it being displaced by cation flux in
thephysiologically relevant, luminal to cyto-
solic, direction. This is the case for either K+
flux driven by a trans-membrane potential
of −40 mV or by Ca2+ flux driven by a
luminal to cytosolic concentration gradient
(the flux equivalent to Ca2+ release from the
SR) (Fig. 1G). Further, flecainide did not
influence RyR2 gating and had negligible
effect on the charge-compensating K+
current carried collectively by RyR2 and the
SR K+ channel during Ca2+ release. Based
on these observations we concluded that
the efficacy of flecainide in the treatment
of CPVT is not the result of a direct inter-
action with RyR2. Given this, we believe
that the inclusion of parameters describing
block of RyR2 by flecainide in the models
used in Yang et al. (2016) is unjustified
and will inevitably lead to spurious
conclusions.
(2) Block of Na+ channel by flecainide
A key factor in the conclusion of Yang
et al. (2016) that block of the Na+ channel
alone is insufficient to explain flecainide
efficacy inCPVTwas provided bymodelling
flecainide’s action in the absence of RyR2
block. However, by their own admission,
the IC50 used in the model to describe
flecainide’s inhibition of Ca2+ waves ‘does
not separate out external contributions to
this parameter, such as lowered junctional
Ca2+ brought about by INCX activity via
lowered [Na+]’ resulting from block of INa,
as proposed by Sikkel et al. (2013). It would
be very interesting to see if inclusion of this
potential mechanism of action of flecainide
in the model could provide an alternative
explanation for the efficacy of flecainide in
CPVT.
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